0000874015-24-000194.txt : 20240904 0000874015-24-000194.hdr.sgml : 20240904 20240904204224 ACCESSION NUMBER: 0000874015-24-000194 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240202 FILED AS OF DATE: 20240904 DATE AS OF CHANGE: 20240904 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cadoret-Manier Onaiza CENTRAL INDEX KEY: 0001799355 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-19125 FILM NUMBER: 241279413 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT STREET 2: C/O IONIS PHARMACEUTICALS, INC. CITY: CARLSBAD STATE: CA ZIP: 92010 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: IONIS PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000874015 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 330336973 STATE OF INCORPORATION: CA FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 BUSINESS PHONE: 7609319200 MAIL ADDRESS: STREET 1: 2855 GAZELLE COURT CITY: CARLSBAD STATE: CA ZIP: 92010 FORMER COMPANY: FORMER CONFORMED NAME: ISIS PHARMACEUTICALS INC DATE OF NAME CHANGE: 19930328 4/A 1 primary_doc.xml PRIMARY DOCUMENT X0508 4/A 2024-02-02 2024-02-02 0 0000874015 IONIS PHARMACEUTICALS INC IONS 0001799355 Cadoret-Manier Onaiza 2855 GAZELLE COURT C/O IONIS PHARMACEUTICALS, INC. CARLSBAD CA 92010 0 1 0 0 EVP,Chf GL Pdt Str & Oper Ofc 0 Common Stock 2024-02-02 4 S 0 2162 49.602 D 35788 D The original Form 4 filed on February 2, 2024 reported 2,125 restricted stock units sold by the reporting person which has been revised by this amendment to reflect the actual amount of shares sold and beneficially owned by Ms. Cadoret-Manier. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $49.60 to $49.62 inclusive. The reporting person undertakes to provide to Ionis Pharmaceuticals, Inc. any security holder of Ionis Pharmaceuticals, Inc. or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) on this Form 4. Patrick R. O'Neil, attorney-in-fact For: Onaiza Cadoret-Manier 2024-09-04